Inflammatory Disease News and Research

RSS

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.

10 Mar 2010

Abbott announces definitive agreement to acquire Facet Biotech

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

9 Mar 2010

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.

9 Mar 2010

Salmonella-infected mice help understand how symptoms of HLH develop

A new University of Colorado at Boulder study shows mice infected with the bacteria salmonella develop clinical signs consistent with a deadly and poorly understood human inflammatory disease, a finding that may lead to new therapies.

26 Feb 2010

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease. This increase in anti-apolipoprotein (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP) may contribute to the development of atherosclerosis in SLE patients, placing them at risk for cardiovascular disease (CVD).

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

Changes in vaginal pH make women more susceptible to infections

Changes in vaginal pH as a result of common “pH triggers” make women more susceptible to infections such as bacterial vaginosis (BV). Understanding how the vaginal environment responds to pH fluctuation helps health professionals prevent and treat these conditions.

18 Feb 2010

Pediatric patients face number of cardiac conditions that can impact their health

While heart disease is traditionally associated with adults, pediatric patients face a number of cardiac conditions that can impact their health.

18 Feb 2010

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

AstraZeneca and Rigel Pharmaceuticals today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications.

16 Feb 2010

getSTDtested.com launches "Kiss Chlamydia Goodbye" campaign

getSTDtested.com, a physician driven, STD testing and treatment online clinic today announced a campaign called "Kiss Chlamydia Goodbye" to encourage young women to take action to prevent chlamydia.

12 Feb 2010

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

11 Feb 2010

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

10 Feb 2010

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas. Genentech and Roche also have a non-exclusive right to manufacture, develop and market diagnostic tests for group 1 influenza.

9 Feb 2010

Blood flowing with force protects against dangerous clogs in blood vessels

It is second nature for most of us that exercise protects against heart attack and stroke, but researchers have spent 30 years unraveling the biochemistry behind the idea. One answer first offered by researchers at the University of Rochester Medical Center is that athletic hearts push blood through arteries with greater force, which alone triggers reactions that protect against dangerous clogs in blood vessels.

29 Jan 2010

U.S. study finds improved mortality outcomes for children with rheumatic diseases

A recent study by researchers from the Cleveland Clinic found that the overall mortality rate in the U.S. for all pediatric patients with rheumatic diseases was not worse than the age and sex-adjusted population.

28 Jan 2010

Elevated cytokine levels are early indicator of rheumatoid arthritis

Researchers from University Hospital in Umea, Sweden, have identified several cytokines, cytokine-related factors, and chemokines that increase significantly prior to rheumatoid arthritis (RA) disease onset. These findings confirm those of earlier studies which suggest that the risk of developing RA can be predicted and disease progression may be prevented.

28 Jan 2010

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.

12 Jan 2010

Genentech's ACTEMRA approved to treat RA

Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

8 Jan 2010

Amira Pharmaceuticals achieves another development milestone in its FLAP program

Amira Pharmaceuticals, Inc. announced today that it has achieved another development milestone in its FLAP program, which is partnered with GlaxoSmithKline. This milestone is related to the successful development of a solid dose formulation, which is critical for future development and commercialization activities.

8 Jan 2010

Frequent chlamydia screening does not reduce infection in teenage girls

Frequent testing and treatment of infection does not reduce the prevalence of chlamydia in urban teenage girls, according to a long term study by Indiana University School of Medicine researchers published in the January 1, 2010 issue of the Journal of Infectious Diseases.

8 Jan 2010

Inflammatory Disease News and Research

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

Abbott announces definitive agreement to acquire Facet Biotech

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Salmonella-infected mice help understand how symptoms of HLH develop

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

Changes in vaginal pH make women more susceptible to infections

Pediatric patients face number of cardiac conditions that can impact their health

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

getSTDtested.com launches "Kiss Chlamydia Goodbye" campaign

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

Blood flowing with force protects against dangerous clogs in blood vessels

U.S. study finds improved mortality outcomes for children with rheumatic diseases

Elevated cytokine levels are early indicator of rheumatoid arthritis

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

Genentech's ACTEMRA approved to treat RA

Amira Pharmaceuticals achieves another development milestone in its FLAP program

Frequent chlamydia screening does not reduce infection in teenage girls

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News